Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid (siRNA), Givosiran, in Patients with Acute Hepatic Porphyria.

Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid (siRNA), Givosiran, in Patients with Acute Hepatic Porphyria. …………… Agarwal S, Simon AR, Goel V, Habtemariam BA, Clausen VA, Kim JB, Robbie GJ. Clin Pharmacol Ther. 2020 Jan 29. PubMed

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. …………… Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O’Dea L, Witztum JL; AKCEA-APO(a)-LRx Study Investigators. N Engl J Med. 2020 Jan 1. PubMed

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis.

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis. …………… Sutherland JE, Hettinger JL, Chan A, Gilbert J, Warner GL, Davis WP. Nucleic Acid Ther. 2019 Dec 10. PubMed